An observational study suggests coprescription of Phosphodiesterase Type 5 Inhibitors (i.e., sildenafil) and oral Nitrates is not associated with increased risk of adverse cardiovascular outcomes in male patients with ischemic heart disease.
20 Apr, 2022 | 10:11h | UTCCommentaries:
PDE5 Inhibitors Prescribed for Men on Oral Nitrates for IHD – HealthDay